Quinolinone Crystal Form Selection for Drug Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug development lacks consideration for polymorphism, which affects the stability, solubility, and bioavailability of 2-(4-hydroxy-1-methyl-2-oxo-7-phenoxy-1,2-dihydroquinoline-3-carboxamido)acetic acid, impacting its efficacy in treating HIF-related and EPO-related diseases.
Innovation Solution
Development of crystal forms I and II of the compound, characterized by specific X-ray diffraction patterns and thermal properties, enhancing stability and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the compound is used without considering crystal form polymorphism, then the development process is simpler, but the stability, solubility, and bioavailability are compromised
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing different crystal forms (polymorphs) of the compound with distinct physical properties. Crystal form I was selected based on its superior stability, solubility, and bioavailability parameters compared to other forms. This involves changing the crystalline structure parameters to optimize drug performance while maintaining manufacturing feasibility through established crystallization protocols.
Solution Approach 2:
The patent implements preliminary action by conducting comprehensive crystal form characterization and selection during the early drug development stage. X-ray diffraction patterns, thermal properties, and solubility studies were performed in advance to identify the most suitable crystal form (Form I) before proceeding to clinical development, thereby preventing later stability and bioavailability issues.
2Reliability
If crystal form I is used, then stability and solubility are improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent resolves this contradiction by optimizing crystallization parameters (solvent selection, temperature profiles, pH conditions) to produce Crystal form I through a controlled but manageable process. The specific parameters identified include using appropriate solvents and temperature ranges that favor Form I crystallization, balancing manufacturing complexity with product quality requirements.
3Ease of manufacture
If crystal form II is used, then the initial synthesis is easier, but the compound is unstable and prone to transformation
Solution Approach 1:
The patent applies preliminary action by performing stability studies and transformation risk assessments on Crystal form II during the evaluation phase. The potential for transformation to other crystal forms was identified as a risk, leading to the selection of the more stable Crystal form I for further development, thereby preventing future stability issues before they impact the product.
Solution Approach 2:
The patent implements preliminary anti-action by taking measures to prevent crystal form transformation. This includes establishing storage conditions and manufacturing protocols that maintain Crystal form I stability, and potentially using additives or processing conditions that inhibit transformation to less stable forms, thereby counteracting the inherent instability risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystal form I exhibits improved stability, solubility, and biological activity, suitable for pharmaceutical use, while form II is unstable and prone to transformation.
Implementation Method 1
the X-ray powder diffraction pattern of the crystal form I has diffraction peaks at the following 2θ angles: 6.20° ± 0.2°, 18.16° ± 0.2°, 19.30° ± 0.2°, 26.89° ± 0.2°, 27.31° ± 0.2°
Implementation Method 2
the differential scanning calorimetry pattern of the crystal form I comprises an endothermic peak of 222.82°C ± 3°C
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a crystal form of a quinolinone compound and a use thereof. The present invention further relates to a pharmaceutical composition comprising the crystal form, and a use of the crystal form or the pharmaceutical composition in the preparation of a drug for the treatment and prevention of HIF-related and/or EPO-related diseases (such as anemia).